Table 1.
Baseline characteristics at SARS-CoV-2 infection of the cohort
| Variable | Population N = 14 |
|---|---|
| Age, years, median (ranges) | 60 (33–79) |
| Male, n (%) | 9 (64) |
| Time since transplantation, months (ranges) | 116 (10–332) |
| Treated hypertension, n (%) | 10 (71) |
| Treated diabetes, n (%) | 3 (21) |
| Overweight-obesity, n (%) | 8 (57) |
| Treated dyslipidemia, n (%) | 11 (79) |
| Prior anti-SARS-CoV-2 vaccine, n (%) | |
| 4 doses | 10 (71) |
| 3 doses | 3 (21) |
| 0 dose | 1 (8) |
| Anti-RBD antibody level prior infection, n (%) | |
| >250 BAU/ml | 8 (57) |
| 0-250 BAU/ml | 2 (14) |
| 0 | 4 (29) |
| Prior COVID-19 infection, n | 0 |
| CYP3A5 genotype, n (%) | |
| 3∗/3∗ | 8 (57) |
| 1∗/3∗ | 2 (14) |
| CYP3A4 genotype, n (%) | |
| 1∗/1∗ | 7 (50) |
| Immunosuppression at admission, n (%) | |
| Immediate release tacrolimus | 1 (7) |
| Slow-release tacrolimus | 11 (79) |
| Mycophenolate mofetil | 11 (79) |
| Cyclosporine | 2 (14) |
| Azathioprine | 1 (7) |
| Steroids | 14 (100) |
| Nirmatrelvir-ritonavir dose, n (%) | |
| 300/100 mg | 5 (36) |
| 150/100 | 9 (64) |
CYP, cytochrome P450; RBD, receptor-binding domain.